

Cellmid Limited

11:20 09 Apr 2018

Cellmid convening global meeting of midkine researchers in Germany

Cellmid Limited (ASX:CDY) will be convening the 5th Midkine Symposium in Munich, Germany between 3rd and 5th May 2018.

The symposium will be a global meeting of key opinion leaders, clinicians and research scientists involved in midkine (MK) research.

READ: Cellmid strengthens its position in hair and skin care market with leading anti-ageing product

The event follows on the success of the previous four scientific meetings on midkine held in Sydney (2010), Istanbul (2012), Kyoto (2014) and Budapest (2016).

Assessing midkine antibodies in chronic heart failure

Midkine is a promising molecule in drug development. It is a heparin-binding growth factor that promotes cell growth, survival, differentiation and cell migration.

It is almost undetectable in healthy adults, however, is upregulated as part of the pathogenesis (development) of certain chronic diseases.

Munich has been chosen for the symposium as it is the home Ludwig Maximilian University (LMU), where researchers are currently assessing Cellmid's midkine antibodies in a model of chronic heart failure.

READ: Cellmid enters exclusive distribution agreement for anti-ageing skincare product

The research at LMU is the subject of a recently filed patent application by Cellmid and is expected to deliver vital data and add to the company's already substantial midkine asset portfolio.

Promoting interactions between midkine researchers

The symposium will host delegates from twelve countries with expertise in various therapeutic and diagnostic fields and will enhance interactions between leading researchers within the midkine community.

Previous meetings resulted in a number of collaborations that continue to provide vital progress for Cellmid's therapeutic programs including the recently completed clinical studies carried out at the University of Gothenburg, Sweden.

The study in Sweden demonstrated that midkine is associated with prostate cancer progression and treatment resistance.

Price: 0.185

Market Cap: \$22.33 m

1 Year Share Price Graph



Share Information

Code: CDY

Listing: ASX

52 week High Low
0.49 0.083

Sector: Pharma & Biotech

Website: www.cellmid.com.au

Company Synopsis:

Cellmid Ltd (ASX:CDY) is an Australian life sciences company with lead programs in multiple disease indications.

action@proactiveinvestors.com.au

Symposium to be led by Dr Ludwig Weckbach

The symposium will be hosted by the team led by clinician scientist Dr Ludwig Weckbach, Cellmid's research partner based at the Biomedical Center and Department of Cardiology, LMU.

Dr Weckbach will be welcoming symposium delegates as well presenting his group's innovative discoveries demonstrating the clinical potential of therapeutic antibodies targeting midkine for chronic heart failure.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand (\$25,000) dollars.